The Medicare program has been negotiating the prices of its most expensive prescription drugs for the first time in its history, but until now that power stopped at the pharmacy counter. The current round changes that. For the first time, the negotiation reaches medications that a patient never picks up in a bottle, the drugs administered in a doctor’s office or clinic by injection or infusion. For older patients who rely on these treatments, the shift aims squarely at some of the largest out-of-pocket bills in medicine.
What changed in the newest negotiation cycle
Federal officials confirmed the expansion when the Centers for Medicare and Medicaid Services announced the third cycle of the drug price negotiation program, selecting a new group of high-cost medicines and, for the first time, including drugs paid for under the program’s medical benefit rather than only its pharmacy benefit. Earlier rounds had targeted pills and other products a patient obtains through a pharmacy. This cycle crosses into the category of provider-administered drugs, the treatments given in a clinical setting and billed differently from anything filled at a drugstore.
Free retirement updates: Plain-English help on keeping more of your money in retirement lands in the free Retirement Shield newsletter, which covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
Why office-administered drugs were untouched before
Medicare pays for prescription drugs through two separate channels. One covers medicines a patient fills at a pharmacy and takes at home. The other covers drugs a clinician administers directly, such as infusions and injections delivered during a visit. The negotiation program launched by focusing on the pharmacy side, where high-cost pills for conditions like diabetes, blood clots, and heart failure drove enormous spending. The provider-administered side, which includes many cancer therapies and specialty biologics, sat outside the first rounds. Bringing it in matters because these clinic-based drugs are frequently among the priciest treatments Medicare covers, and patients often owe a percentage of the cost rather than a flat copay.
When the negotiated prices take effect
The negotiation itself plays out over roughly two years between the government and each drug’s maker, with the resulting maximum fair prices scheduled to take effect at the start of 2028 for this cycle. In other words, the prices being hammered out now are set to reach patients on January 1, 2028, once the negotiation concludes. That lag is built into the program’s design: drugs are selected, negotiations run their course, and the agreed prices apply in a later benefit year. Independent analysts at KFF track the program’s timeline and selected-drug lists, which lay out how each cycle moves from selection to a live negotiated price.
The money angle for older patients
The reason this reaches older Americans in the wallet is the way cost-sharing works on clinic-administered drugs. Because many of these treatments are billed under the medical benefit, a patient can owe a coinsurance percentage of a very large sticker price, and for a costly cancer infusion that share can run into serious money over a course of treatment. Lowering the underlying price that Medicare recognizes can pull down the dollar figure that coinsurance is calculated from. Combined with the newer annual cap on out-of-pocket prescription costs on the pharmacy side, the direction of policy is toward shrinking the catastrophic bills that once forced some retirees to skip or ration treatment.
How the coinsurance math works on an infusion
The reason a lower negotiated price reaches a patient’s wallet lies in how office-administered drugs are billed. Under the medical benefit, a beneficiary typically owes a percentage of the drug’s approved cost rather than a flat copay. Picture an infused therapy with an approved price of $12,000 per session and a 20 percent share: the personal cost is about $2,400 each time, and a treatment course of several sessions multiplies that quickly. If negotiation trims the recognized price by, say, 30 percent to roughly $8,400, the same 20 percent coinsurance drops to about $1,680, a saving near $720 per session before any other protection is counted. Because the coinsurance is a percentage of the sticker price, lowering that price lowers the patient’s share in direct proportion, which is what makes reaching these clinic-based drugs so significant for the households that depend on them.
What is still uncertain
None of this is fully settled. The negotiation is a process, not a finished result, and the exact prices for the office-administered drugs in this cycle will not be known until it concludes, ahead of the 2028 effective date. The program has also faced legal challenges from drug manufacturers, and the list of affected medicines can shift as the cycle proceeds. A patient currently receiving one of the selected infusions will not see a changed price immediately; the relief, if the negotiation holds, arrives when the new prices go live in the applicable benefit year. Until then, the practical guidance is to keep watching how a specific treatment is classified and billed.
How a patient can prepare
Someone who depends on an injected or infused Medicare-covered drug can take stock now rather than wait. Reviewing how a treatment is billed, whether under the medical benefit or the pharmacy benefit, clarifies which set of cost protections applies. Asking a provider or plan whether a particular medication appears on the negotiated list, and confirming the year any new price takes effect, avoids false expectations of an overnight discount. For households budgeting around expensive ongoing treatment, understanding that negotiated relief on office-administered drugs is coming, but is dated to a future benefit year, is the difference between a realistic plan and a disappointed one.
This article was researched and drafted with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
